GeoVax Announces First Patients Vaccinated In Phase 2 Clinical Trial Of COVID-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia
Portfolio Pulse from Benzinga Newsdesk
GeoVax has announced the vaccination of the first patients in a Phase 2 clinical trial of its COVID-19 vaccine booster in patients with Chronic Lymphocytic Leukemia. The company is seeking to improve immune response compared to mRNA vaccines. Full patient enrollment is expected within six months.
August 10, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax's announcement of the first vaccinations in its Phase 2 clinical trial could potentially boost investor confidence in the company's COVID-19 vaccine booster. Full patient enrollment within six months could also indicate progress in the company's vaccine development.
The commencement of Phase 2 clinical trials indicates progress in GeoVax's vaccine development, which could positively impact the company's stock. The potential for improved immune response compared to mRNA vaccines could also increase investor interest in the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100